Immix Biopharma (IMMX) Accumulated Expenses (2020 - 2026)

Immix Biopharma has disclosed Accumulated Expenses across 7 years of filings, most recently posting $880671.0 for Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $880671.0, up 20.34% year-over-year; the trailing twelve-month figure through Mar 2026 was $880671.0 (up 20.34% YoY), and the FY2025 annual result was $942163.0, up 43.15% from the prior year.
• Accumulated Expenses came in at $880671.0 for Q1 2026 at Immix Biopharma, down from $942163.0 in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $942163.0 in Q4 2025 to a low of $9407.0 in Q1 2022.
• The 5-year median for Accumulated Expenses is $577854.0 (2023), against an average of $535147.6.
• Across the five-year window, Accumulated Expenses rose 13.9% in 2024 and soared 311.75% in 2025, its largest moves.
• Immix Biopharma's Accumulated Expenses stood at $9407.0 in 2022, then soared by 6042.81% to $577854.0 in 2023, then rose by 13.9% to $658161.0 in 2024, then soared by 43.15% to $942163.0 in 2025, then declined by 6.53% to $880671.0 in 2026.
• The last three Accumulated Expenses figures came in at $880671.0 (Q1 2026), $942163.0 (Q4 2025), and $438243.0 (Q3 2025), per Business Quant data.